Rebecca Hudson appointed new CFO at Nova Mentis
Biotechnology company Nova Mentis Life Science Corp. has announced the appointment of its new Chief Financial Officer, Rebecca Hudson, who will bring her knowledge of corporate finance, accounting and risk management experience to the management team.
Founded in 2004, Nova Mentis Life Science Corp. is headquartered in Vancouver, Canada. Nova develops diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders and aspires to diagnose and treat chronic conditions, such as:
- Autism spectrum disorder (ASD)
- Fragile X Syndrome (FXS)
Hudson has a passion for healthcare research
After securing a Bachelor’s Degree and a Masters of Accounting from the University of Waterloo, Hudson built more than two decades of experience as a Chartered Professional Accountant (CPA, CA) in:
- Accounting and financial reporting
- Corporate finance
- Risk management
- Financial audit and corporate governance
In addition, she has served as CFO for publicly-listed resource companies across Europe and North America. Now she is ready to bring her passion for research to Nova.
Leading a team and building partnerships
“Ms. Hudson has a demonstrated track record of financial management and is known for being a strategic leader who has the necessary expertise to build operations and cultivate partnerships to deliver financial results”, said Will Rascan, NOVA’s CEO & President.
“We are delighted she has joined our team and look forward to the guidance and leadership she will provide.”
“I’m excited to take on this new role and use my experience to help drive corporate strategy and the Company’s growth”, says Rebecca Hudson. “I share NOVA’s commitment to financial discipline and their passion for researching novel approaches to help treat neuroinflammatory disorders such as autism spectrum disorder, diabetes and obesity. I look forward to being part of the team and contributing to its success.”
Former CFO Jamie Robinson has been thanked for his hard work at NOVA.
